143 completed, 118 recruiting, 94 unknown, 63 active not recruiting. 339 Phase 2, 102 Phase 1, 65 Phase 3, 29 Not applicable, 11 Phase 4.
Follow lenvatinib: new trials by email Literature Review of lenvatinib trials Research Report on lenvatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| Lenvatinib in Patients With Advanced Parathyroid Carcinoma Lenvatinib - Parathyroid Carcinoma | Phase 2 | Not yet recruiting | Yonsei University | 18 | 2026-11-01 | 2026-09-28 |
| Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer Lenvatinib, Tislelizumab, Gefitinib - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 120 | 2026-11-01 | 2026-09-21 |
| Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 35 | 2026-10-01 | 2026-09-15 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 492 | 2026-10-01 | 2026-09-23 |
| Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV | Phase 2 | Recruiting | Sun Yat-sen University | 28 | 2026-10-01 | 2026-09-29 |
| Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer Lenvatinib, Pembrolizumab - Anal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 17 | 2026-09-30 | 2026-07-02 |
| PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 40 | 2026-09-30 | 2026-09-18 |
| Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib, Cryoablation - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Fudan University | 180 | 2026-09-20 | 2026-09-21 |
| MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer Becotatug Vedotin (MRG003), Lenvatinib, Anti-PD-1 Inhibitor (Continuation of Prior Treatment) - Thyroid Cancer, Tumor | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 | 2026-09-20 | 2026-10-14 |
| Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 20 | 2026-09-01 | 2026-09-03 |
| A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma Iparomlimab and Tuvonralimab in combination with Lenvatinib - Urologic Neoplasms | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 54 | 2026-08-15 | 2026-08-03 |
| STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation Lenvatinib, TMZ (Temozolomide), radiotherapy - Glioma, Glioblastoma (GBM) | Phase 2 | Not yet recruiting | Dongguan People's Hospital | 138 | 2026-08-10 | 2026-08-10 |
| Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance Pembrolizumab, Lenvatinib - Recurrent Endometrial Cancer | Phase 2 | Recruiting | University of Miami | 46 | 2026-08-06 | 2026-09-24 |
| Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC, EP/EC - Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), QL1706 | Phase 2 | Not yet recruiting | West China Hospital | 92 | 2026-08-01 | 2026-07-31 |
| Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem EG-007, Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 2 | Not yet recruiting | Evergreen Therapeutics, Inc. | 28 | 2026-08-01 | 2025-12-08 |
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
| Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II Becotatug Vedotin, Tislelizumab, Lenvatinib - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 36 | 2026-08-01 | 2026-07-16 |
| Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment Pembrolizumab 200 mg Q3W, Lenvatinib 20mg QD - ccRCC | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 108 | 2026-08-01 | 2026-03-10 |
| Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc) | Phase 3 | Not yet recruiting | Zhejiang Cancer Hospital | 140 | 2026-07-01 | 2026-07-14 |
Showing 20 of 525. Sign in to see all of them.
Carcinoma, Hepatocellular (153) · Carcinoma, Renal Cell (37) · Parkinson Disease 4, Autosomal Dominant Lewy Body (34) · Neoplasms (30) · Cholangiocarcinoma (28) · Endometrial Neoplasms (19) · Liver Neoplasms (19) · Thyroid Neoplasms (18) · Biliary Tract Neoplasms (16) · Melanoma (16) · Carcinoma, Non-Small-Cell Lung (13) · Stomach Neoplasms (13) · Recurrence (10) · Neoplasm Metastasis (9) · Breast Neoplasms (8)
Merck Sharp & Dohme LLC (45) · Eisai Inc. (43) · Sun Yat-sen University (40) · Fudan University (26) · Tianjin Medical University Cancer Institute and Hospital (18) · Peking Union Medical College Hospital (15) · Eisai Co., Ltd. (14) · Tongji Hospital (11) · M.D. Anderson Cancer Center (10) · RenJi Hospital (8) · Second Affiliated Hospital of Guangzhou Medical University (7) · Shanghai Zhongshan Hospital (7) · Chen Xiaoping (6) · Memorial Sloan Kettering Cancer Center (6) · Zhejiang Cancer Hospital (6)
China (269) · United States (146) · Spain (61) · South Korea (58) · Italy (57) · Japan (57) · France (56) · Australia (48) · United Kingdom (47) · Canada (45) · Germany (38) · Taiwan (37) · Poland (35) · Russia (33) · Israel (32)
Peng Wang, MD (8) · Ming Shi, MD (7) · Haitao Zhao, MD (3) · Soo Chin Lee (3) · Alan Ho, MD, PhD (2) · Feng Duan, MD (2) · Floor Backes, MD (2) · Gaojun Teng, MD (2) · Guoliang Shao, MD (2) · Hao Feng, MD., Ph.D. (2) · Jian Zhou (2)
PMID 29433850, PMID 33300372, PMID 33198671, PMID 20375404, PMID 23860537, PMID 28818953, PMID 30207593, PMID 32265508, PMID 32716739, PMID 32832493, PMID 34087115, PMID 34416158, PMID 34562750, PMID 38039993, PMID 38159809, PMID 39941845, PMID 40812353, PMID 42167105, PMID 11282421, PMID 12778165, PMID 12806613, PMID 14667750, PMID 15043519, PMID 15319238, PMID 16557381, PMID 17410014, PMID 18596824, PMID 19095497, PMID 19097774, PMID 20930041, PMID 21372218, PMID 21502559, PMID 21847048, PMID 21847058, PMID 21874260, PMID 21953501, PMID 22339891, PMID 22525820, PMID 22537432, PMID 23043667, PMID 23485770, PMID 23676418, PMID 24146220, PMID 24681130, PMID 24769639, PMID 24852116, PMID 24974848, PMID 25027973, PMID 25047123, PMID 25275083
2023 (28), 2019 (13), 2018 (10), 2017 (7), 2015 (3), 2016 (3), P30CA015083 (3), 2025 (2), P30CA033572 (2), P30CA138292 (2), 2004 (1), 2009 (1), 2014 (1), U10CA180868 (1), U10CA180888 (1)